AI assistant
Sending…
Lexaria Bioscience Corp. — Director's Dealing 2009
Oct 21, 2009
34983_dirs_2009-10-20_185d8b16-2bf0-4d71-83b0-ceae61f39edf.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: LEXARIA CORP. (LXRP)
CIK: 0001348362
Period of Report: 2009-10-19
Reporting Person: BUNKA CHRISTOPHER (Director, Chairman/CEO/President, 10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2009-10-19 | Common Shares | P | 10000 | $0.149 | Acquired | 454805 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Shares | 2033998 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Warants | $2.4 | 2009-11-09 | Common Shares (291700) | 291700 | Indirect |
| Warrants | $0.2 | 2011-07-10 | Common Shares (1600000) | 1600000 | Indirect |
| Stock Options | $0.2 | 2011-04-26 | Common Shares (100000) | 100000 | Direct |
| Stock Options | $0.2 | 2011-07-20 | Common Shares (100000) | 100000 | Direct |
| Stock Options | $0.2 | 2011-07-20 | Common Shares (18750) | 18750 | Direct |
| Convertible Debt | $0.05 | 2009-10-27 | Common Shares (43333) | 43333 | Direct |
| Convertible Debt | $0.05 | 2010-10-27 | Common Shares (43333) | 43333 | Direct |
| Convertible Debt | $0.05 | 2009-10-27 | Common Shares (32500) | 32500 | Indirect |
| Convertible Debt | $0.05 | 2010-10-27 | Common Shares (32500) | 32500 | Indirect |
Footnotes
F1: Chris Bunka is the sole owner of CAB Financial Services Ltd.
F2: On July 8, 2009, the exercise priced was reduced from $0.80.
F3: On July 8, 2009, the exercise price was changed from $0.12.
F4: On July 9, 2009, the exercise price was changed from $0.45.
More from Lexaria Bioscience Corp.
Interim / Quarterly Report
2026
Apr 13
Director's Dealing
2026
Mar 18
Regulatory Filings
2026
Feb 6
Regulatory Filings
2026
Jan 28
Regulatory Filings
2026
Jan 28
Delisting Announcement
2026
Jan 14
Regulatory Filings
2026
Jan 14
Interim / Quarterly Report
2026
Jan 13
Regulatory Filings
2025
Dec 29
Regulatory Filings
2025
Dec 19